XML 55 R43.htm IDEA: XBRL DOCUMENT v3.22.1
License, Collaboration and Other Significant Agreements - International Collaboration and License Agreement with Otsuka Pharmaceutical Co. Ltd. (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2022
USD ($)
performance_obligation
Mar. 31, 2021
USD ($)
Mar. 31, 2017
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Recognized revenue $ 61,699 $ 52,304      
Deferred revenue 75,796        
Short-term deferred revenue 10,440     $ 20,906  
Deferred revenue, net of current portion 65,356     21,474  
Accounts receivable          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable 24,316 3,539   19,094 $ 3,045
Prepaid expenses and other current assets          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable 3,970 1,916   4,309 1,722
Accounts payable          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred revenue 319 0   3,171 $ 7,227
License, collaboration and other revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Recognized revenue $ 20,251 21,896      
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Number of performance obligations | performance_obligation 3        
Transaction price $ 316,900        
Reimbursement of costs     $ 200    
Estimated current global development costs subsequent to March 31, 2017 243,700        
Deferred revenue 10,221        
Short-term deferred revenue 4,248        
Deferred revenue, net of current portion 5,973        
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Accounts receivable          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable 11,300        
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Prepaid expenses and other current assets          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Accounts receivable 1,200     1,300  
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Accounts payable          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Deferred revenue       $ 900  
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | License, collaboration and other revenue          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Recognized revenue 5,503 $ 6,972      
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed HIF Product          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Eligible milestone payments (up to) $ 17,000        
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed HIF Product | Minimum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Eligible milestone payments, period 12 months        
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed HIF Product | Maximum          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Eligible milestone payments, period 24 months        
Otsuka Pharmaceutical Company. Ltd. | Otsuka International Agreement | Licensed Products          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Eligible milestone payments (up to) $ 525,000        
Otsuka Pharmaceutical Company. Ltd. | Up Front Non Refundable And Non Creditable | Otsuka International Agreement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Upfront cash payment received $ 73,000